Jeff Tangney'un ücretlendirmesi Doximity'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Dec 31 2024	n/a	n/a	US$201m
Sep 30 2024	n/a	n/a	US$174m
Jun 30 2024	n/a	n/a	US$161m
Mar 31 2024	US$299k	US$295k	US$148m
Dec 31 2023	n/a	n/a	US$138m
Sep 30 2023	n/a	n/a	US$123m
Jun 30 2023	n/a	n/a	US$119m
Mar 31 2023	US$244k	US$240k	US$113m
Dec 31 2022	n/a	n/a	US$119m
Sep 30 2022	n/a	n/a	US$141m
Jun 30 2022	n/a	n/a	US$148m
Mar 31 2022	US$243k	US$240k	US$133m
Dec 31 2021	n/a	n/a	US$107m
Sep 30 2021	n/a	n/a	US$57m
Jun 30 2021	n/a	n/a	US$30m
Mar 31 2021	US$21m	US$240k	US$22m

Tazminat ve Piyasa: Jeff 'nin toplam tazminatı ($USD 298.87K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 14.24M ).

Tazminat ve Kazançlar: Jeff 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Jeff Tangney (51 yo)

15yrs

Görev süresi

US$298,869

Tazminat

Mr. Jeffrey A. Tangney, also known as Jeff, Co-Founded Doximity, Inc. in 2010 and has been its Chief Executive Officer and Director since April 2010 and serves as its Chairperson. Mr. Tangney also serves a...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Tangney	Co-Founder	15yrs	US$298.87k	26.53% $ 2.8b
Nate Gross	Co-Founder & Chief Strategy Officer	no data	US$305.47k	0.26% $ 27.3m
Anna Bryson	Chief Financial Officer	4.2yrs	US$3.87m	0.16% $ 17.3m
Jennifer Chaloemtiarana	General Counsel & Corporate Secretary	4.7yrs	US$603.94k	0.0031% $ 333.8k
Craig Overpeck	Senior Vice President of Commercial Operations	1.9yrs	US$5.21m	0.011% $ 1.2m
Shari Buck	Co-founder and SVP People & Ops	no data	Veri yok	Veri yok
Jey Balachandran	Chief Technology Officer	no data	Veri yok	Veri yok
Perry Gold	Head of Investor Relations	no data	Veri yok	Veri yok
Bruno Miranda	Senior Vice President of Engineering	no data	Veri yok	Veri yok
Joel Davis	Senior Vice President of Product	no data	Veri yok	Veri yok
Ben Greenberg	Senior VP & GM Commercial Products	1.9yrs	Veri yok	Veri yok
Lisa Greenbaum	Chief Commercial Officer	no data	Veri yok	Veri yok

4.2yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: DOCS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Tangney	Co-Founder	15yrs	US$298.87k	26.53% $ 2.8b
Barry Chaiken	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Timothy Cabral	Independent Director	4.6yrs	US$239.94k	0% $ 0
Kevin Spain	Independent Director	14.1yrs	US$241.94k	0.19% $ 20.6m
Lawrence Chin	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Elise Brett	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Bradley Cohn	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Alexander Ding	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Sharon Drost	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Todd Ferris	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Harvey Fishman	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Kira Wampler	Independent Director	5.1yrs	US$233.94k	0.0055% $ 581.4k

9.6yrs

Ortalama Görev Süresi

51.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: DOCS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 9.6 yıldır).

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/04/27 06:51
Gün Sonu Hisse Fiyatı	2025/04/25 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/03/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Doximity, Inc. 27 Bu analistlerden 19, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Vikram Kesavabhotla	Baird
Nisala Weerasuriya	Berenberg
Allen Lutz	BofA Global Research

Doximity Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Co-Founder recently sold US$62m worth of stock

Independent Director notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Recent updates

Doximity, Inc. to Report Q4, 2025 Results on May 15, 2025

Shareholders Are Optimistic That Doximity (NYSE:DOCS) Will Multiply In Value

What Doximity, Inc.'s (NYSE:DOCS) 28% Share Price Gain Is Not Telling You

Co-Founder recently sold US$62m worth of stock

Investor sentiment improves as stock rises 29%

Doximity Q3 Earnings: Outpacing Even Management's Expectations

Price target increased by 27% to US$70.06

Now 24% overvalued after recent price rise

Doximity, Inc. Provides Earnings Guidance for the Fiscal Fourth Quarter Ending March 31, 2025 and Updates Earnings Guidance for the Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

When Should You Buy Doximity, Inc. (NYSE:DOCS)?

Doximity, Inc. to Report Q3, 2025 Results on Feb 06, 2025

Now 21% overvalued after recent price rise

Doximity: Upgraded To Buy Amid Promising Growth And Strong Execution

Here's Why We Think Doximity (NYSE:DOCS) Is Well Worth Watching

Now 24% overvalued after recent price rise

Doximity: Strong Fundamentals And Growth Potential Makes It Attractive

Doximity (NYSE:DOCS) Knows How To Allocate Capital

Investor sentiment improves as stock rises 20%

Chief Financial Officer notifies of intention to sell stock

Earnings Not Telling The Story For Doximity, Inc. (NYSE:DOCS) After Shares Rise 34%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for Its Fiscal Third Quarter Ending December 31, 2024 and Updating Earnings Guidance for Its Fiscal Year Ending March 31, 2025

Independent Director notifies of intention to sell stock

Does This Valuation Of Doximity, Inc. (NYSE:DOCS) Imply Investors Are Overpaying?

Doximity, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Price target increased by 8.5% to US$37.21

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity: Downgrade To Hold On Valuation Concerns

Here's Why Doximity (NYSE:DOCS) Has Caught The Eye Of Investors

Now 22% overvalued after recent price rise

Generative AI And Digital Health Innovations Fuel Robust Revenue Growth And Market Expansion

There's Reason For Concern Over Doximity, Inc.'s (NYSE:DOCS) Massive 27% Price Jump

Investor sentiment improves as stock rises 39%

Chief Financial Officer exercised options and sold US$1.1m worth of stock

Price target increased by 7.1% to US$31.64

Doximity (NYSE:DOCS) Looks To Prolong Its Impressive Returns

New minor risk - Share price stability

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Revenue Guidance for the Second Quarter Ending September 30, 2024 and Fiscal Year Ending March 31, 2025

Doximity Faces Slower Revenue Growth As R&D Costs May Rise

Is Doximity, Inc. (NYSE:DOCS) Trading At A 23% Discount?

Doximity, Inc., Annual General Meeting, Aug 29, 2024

Doximity, Inc. to Report Q1, 2025 Results on Aug 08, 2024

Now 29% undervalued

Now 28% undervalued

At US$27.97, Is It Time To Put Doximity, Inc. (NYSE:DOCS) On Your Watch List?

Now 22% undervalued after recent price drop

Chief Financial Officer notifies of intention to sell stock

Optimistic Investors Push Doximity, Inc. (NYSE:DOCS) Shares Up 26% But Growth Is Lacking

Investor sentiment improves as stock rises 18%

Doximity, Inc. Provides Financial Guidance for the First Quarter Ending June 30, 2024 and Full Year Ending March 31, 2025

Full year 2024 earnings released: EPS: US$0.78 (vs US$0.58 in FY 2023)

Doximity Earnings: Better Than Expected, But Still Mixed Outlook (Rating Upgrade)

Doximity, Inc. (NYSE:DOCS) announces an Equity Buyback for $500 million worth of its shares.

Capital Allocation Trends At Doximity (NYSE:DOCS) Aren't Ideal

Doximity: Significant Upside Remains, But Not Until The Growth Story Returns

Doximity, Inc. to Report Q4, 2024 Results on May 16, 2024

Kessler Topaz Meltzer & Check, LLP Files Securities Fraud Class Action Lawsuit Against Doximity, Inc

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Doximity, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ending March 31, 2024

Price target increased by 7.2% to US$28.17

Doximity, Inc. to Report Q3, 2024 Results on Feb 08, 2024

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Now 21% undervalued

Investor sentiment improves as stock rises 24%

Doximity, Inc. Provides Revenue Guidance for the Fiscal Third Quarter Ending December 31, 2023 and Fiscal Year Ending March 31, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations